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Summary
Methadone substitution is claimed to be the most effective way of pharmacological manage-
ment of human immunodeficiency virus (HIV) positive patients addicted to opioids. Possible 
and clinically the most relevant drug interactions are those between methadone and antire-
troviral agents [13,18,25,32]. HIV causes cognitive impairment by infiltrating the central ne-
rvous system (CNS) in the initial phase of infection. The consequence of this is damage to the 
hippocampus, caudate nucleus, and basal ganglia [2,26].
Eighty-six patients from the substitution program group were examined. The trial was con-
ducted twice: before and about 1.5 hours after the administration of a therapeutic dose of 
methadone. The antisaccades task (AT) and latency task (LT) were performed using a sacca-
dometer diagnostic system.
The statistical analysis showed that the mean duration of latency measured by AT in HIV(-) 
and HIV(+) subjects after the administration of a therapeutic dose of methadone was signifi-
cantly increased (p=0.03 HIV(-); p=0.04 HIV(+)). There was a statistically significant increase 
in the mean latency after the administration of methadone in HIV(+) subjects when compared 
to the control group measured by LT (p=0.03). 
The statistical analysis confirms the change in the saccadic refixation parameters in patients 
addicted to opioids. Methadone influences saccadic dynamic parameters less in HIV(+) than 
in HIV(-) drug users. Oculomotor disturbances are probably related to the neurotropic ef-
fects of HIV leading to damage of the striatum, which plays an important role in psycho-
motor functions. 
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IntroductIon
Administration of psychoactive drugs increases dopami-
nergic receptor stimulation, improves mood and stimula-
tes motor activity. Chronic use of psychoactive substan-
ces can lead to structural and functional changes in the 
central nervous system (CNS) [26]. Patients addicted to 
opioids can experience symptoms similar to those in pe-
ople with structural changes in the cerebral cortex [5,26]. 
According to the concepts of regulation of mental activity 
by cortico-subcortical loops, integrity of all the structures 
constituting the loops is a prerequisite for their physiolo-
gical functioning [2]. There are five known control loops 
linking the subcortical nuclei with the cerebral cortex: 
motor, oculomotor, dorsolateral prefrontal, lateral or-
bitofrontal, and limbic. Any dysfunction of these loops, 
as observed in several psychiatric disorders, as well as in 
psychoactive substance addiction, results in emotional, 
motor and cognitive impairment [7,8,16]. The alteration 
of cortico-subcortical loop function occurs in patients in-
fected with HIV because of the neurotropic properties it 
exhibits. Features of subcortical stupor are found [19,29]. 
The oculomotor loop participates in the control of sacca-
dic eye movements. In order to investigate oculomotor 
disorders in people addicted to psychoactive substan-
ces, examination of eye movement parameters was car-
ried out to assess the impact of psychoactive substances 
on the CNS [7]. The study of eye movement allows one 
to understand the function of the brain. Abnormalities 
of ocular motility frequently reflect the localization of 
a pathological process. The neural structures that con-
trol saccades are widespread in the brain structure; thus 
neurological disorders exhibit a variety of effects on the 
saccadic parameters [23,24]. The movements are highly 
and specifically responsive to all kinds of disturbances 
when motor commands to the contractile muscular fi-
bers are generated and delivered. The impairment of the 
saccadic system is therefore the most sensitive indicator 
of even slight disturbances within the neuromuscular 
system [23].
MaterIal and Methods
Eighty-six patients from the methadone substitution 
program were examined. The study included 32 women 
and 54 men (mean age 39±7.7 years) including 46 HIV(-) 
subjects and 40 HIV(+) subjects managed in a methado-
ne substitution program over a period of 53 months on 
average. All HIV(+) subjects were infected with hepati-
tis C virus (HCV). The mean duration of antiretroviral 
treatment (lamivudine, tenofovir disoproxil fumarate, 
ritonavir, lopinavir/ritonavir) was 51 months (±52.18). 
The trial was conducted twice: before and about 1.5 ho-
urs after the administration of a therapeutic dose of me-
thadone (mean daily dose of methadone: 71.9±(33.4) mg). 
The study included 36 subjects from the control group. 
All the subjects performed the antisaccades task (AT) 
and latency task (LT) twice. The antisaccades task was 
used to assess the relative complexity and vulnerability 
of the underlying decision mechanisms. A subject told to 
look in the direction opposite to a stimulus has to sup-
press the automatic response of looking towards it. This 
leads to delays and errors which are believed to be gene-
rated by completion of the decision processes [22]. The 
latency task is aimed at monitoring visual attention pro-
cesses reflecting conscious attention. It allows detection 
of anomalies in attention management [23]. In the rese-
arch effects of deep brain stimulation (DBS), carried out 
in order to change the saccadic parameters, were ana-
lyzed. A saccadometer is a diagnostic system enabling 
identification of impairment of the CNS functioning at 
the earliest (presymptomatic) stages of a disorder. The 
system allows one to perform strictly quantitative eva-
luation of saccadic dynamics measuring eye movement 
with infrared technology (infra-red oculography). The 
voltage signal generated by the eye movement sensor is 
converted into digital 12-bit samples at a frequency of 
1 kHz. Saccades are detected after exceeding the detec-
tion threshold of 5 deg/s [7,8,16]. The system measures 
eye movements in a horizontal plane with high temporal 
and spatial resolution. The visual stimulus is displayed, 
using miniature laser projectors mounted on the sensor 
forehead plate, in order to stimulate the subject’s visu-
al system. Visual stimulation allows one to carry out a 
number of tests for fast eye movements (saccades) rese-
arch. In all the tests the system provides an opportunity 
to set numerous trials or test duration according to the 
examination needs. The test results (saccadic latency, 
duration, peak velocity and simplified position profile) 
are stored in the device’s memory and can be reviewed 
once the test is finished [8]. 
STATISTICA version 10 was used for data analysis. The 
statistical significance of differences of parameter values 
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between groups (before and after HIV(-), HIV(+), the con-
trol group) was verified using Student’s t test for unpa-
ired samples. Statistical significance of the differences of 
parameter values of both groups (before and after HIV(-), 
HIV(+)) was verified using Student’s t test for dependent 
samples.
results
For statistical analysis HIV (+) and HIV (-) subject gro-
ups were distinguished and compared to the individuals 
from the control group. In the saccadic refixations test 
- latency task it was found that the mean latency before 
the administration of methadone was not statistically 
significantly different between HIV(-) (mean 198.3 ms 
±53.8; p=0.58) and HIV(+) (mean 212.8 ms ±74.4; p=0.015) 
subjects when compared to the individuals from the con-
trol group (mean 189.2 ms ±49.2). The statistical analysis 
showed that the mean latency after the administration of 
methadone in HIV(+) subjects (mean 214.4 ms ±54.4) when 
compared to the control group (mean 189.2 ms ±49.2) was 
significantly increased (p=0.03; t=2.11).
The difference in mean peak velocity of latency before 
the administration of a therapeutic dose of methado-
ne in HIV(-) (mean 421.3 deg/s ±69.8) compared to the 
control group (mean 447.5 deg/s ±54) was not statisti-
cally significant (p=0.06) but it decreased significan-
tly after methadone administration (mean 406.5 deg/s 
±84.1; p=0.01). 
It was observed that the mean amplitude of saccades was 
increased before and after the administration of metha-
done in all research groups (before: HIV(-) mean 10.2 deg 
±0.9; HIV(+) mean 11 deg ±5.1; after: HIV(-) mean 10.6 deg 
±1.4; HIV(+) mean 10.8 deg ±3.9) when compared to the 
control group (mean 9.6 deg ±0.3). Before (p=0.0002) and 
after (p=0.0001) the administration of methadone the 
mean amplitude in the latency task differed significan-
tly in HIV(-) patients treated with the substitution drug 
when compared to individuals from the control group. 
Statistical analysis of the same eye movements parame-
ters (mean peak velocity, mean latency, mean duration, 
mean amplitude) was performed using the antisaccades 
task. From among the members of the study groups, who 
were addicted to opioids, HIV(-) and HIV(+) participants 
of the substitution program were identified. The stati-
stical analysis shows that the mean latency measured by 
the AT after the administration of a therapeutic dose of 
methadone decreased statistically significantly in HIV (-) 
subjects (mean before: 328.51 ms ±159.3; after: 298.74 ms 
±130.03; p=0.04), in contrast to the HIV(+) subjects (mean 
before: 345.8 ms ±128.2; after: 321.65 ms ±112.8), where 
there was no statistically significant difference (p=0.35).
An increase of the mean duration values in HIV(-) (mean 
before: 55.8 ms ±10.8; after: 60 ms ±10.8; p=0.03) and HIV(+) 
(mean before: 60.1 ms ±11.1; after: 65.3 ms ±12.1; p=0.04) 
subjects after the administration of a therapeutic dose of 
methadone was observed. The statistical analysis revealed 
Fig. 1.  Comparison of the mean latency in the latency task after the 
administration of methadone in HIV(+) subjects and individuals from 
the control group
Fig. 2.  Comparison of the mean peak velocity in the latency task after the 
administration of methadone in HIV(-) subjects and individuals from 
the control group
Fig. 3.  Comparison of the mean latency in the AT before and after the 
administration of methadone in HIV(-) subjects
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that it is significant. No statistically significant differen-
ces were found in other parameters of the test (mean am-
plitude [deg] - before: 11.07±3.1 HIV(-), 11.70±3.9 HIV(+); 
after: 11.08±2.8 HIV(-), 11.82±3.4 HIV (+); mean peak ve-
locity [deg/s] - before: 398.09±90.9 HIV(-), 395.60±109.8 
HIV(+); after: 382.06±82.1 HIV(-), 342.40±97.4 HIV (+)).
dIscussIon
The analysis of the latency task results have confirmed 
that the mean latency in HIV (+) subjects is significan-
tly longer after the administration of methadone. The 
mean peak velocity is significantly shorter after metha-
done in HIV(-) subjects. The results may indicate that 
the administration of a therapeutic dose of methadone 
changes the saccadic refixation parameters in subjects 
from all the study groups when compared to the con-
trol group. Methadone influences saccadic dynamic pa-
rameters to a lesser extent in HIV(+) than in HIV(-) drug 
users. Eye movement disturbances are probably related 
to the neurotropic effects of HIV leading to damage of the 
striatum, which plays an important role in psychomo-
tor functions. This has been confirmed by other authors 
[1,6,9,10,12,15,20,28,33]. Several studies have shown that 
the most pronounced effects of HIV infection are corti-
cal atrophy and widespread neuronal loss [1,33]. It was 
demonstrated that in patients with AIDS there is a 3–8% 
prevalence of neuro-ophthalmological disorders [20]. In 
addition, it has been shown that asymptomatic HIV infec-
ted subjects, even in the early stages of infection, exhibit 
oculomotor disturbances [9,10,12,20,28]. Optic nerves of 
HIV infected patients can undergo chronic degeneration 
resulting in axonal loss. The mechanism by which HIV 
induces optic neuropathy emphasizes the key role of tu-
mor necrosis factor alpha (TNF-a) [6,15]. Eye movement 
disturbances can also be related to the interactions of 
antiretroviral drugs and methadone leading to changes 
in methadone concentrations and influencing the regu-
lation of psychomotor activity at the same time [30,31]. 
The results of other research describe drug interactions 
which occurred during dependency and HIV infection 
treatment. It has been proven that there are numero-
us interactions between methadone and antiretroviral 
agents. It has been speculated that antiretroviral medi-
cations themselves can contribute to the decline of co-
gnitive functions [30]. The results of other research have 
proven that certain combination antiretroviral therapy 
cART medications could be neurotoxic [31]. Methadone 
concentration is reduced by concomitant administration 
of some of retroviral agents. The use of lopinavir/ritona-
vir may lead to opioid withdrawal symptoms. [3,4,11]. The 
antiretroviral agents can alter methadone pharmacody-
namics, leading to changes in the clinical picture [14]. 
Pharmacokinetic interactions of methadone commonly 
cause a decrease of the concentrations and reduction of 
effects of concomitantly used agents, which will influence 
psychomotor activity [3]. 
A statistical analysis of the same latency task parameters 
was performed using the antisaccades task. From among 
opioid addicted individuals being treated with metha-
done HIV(+) and HIV(-) subjects were identified. It was 
found that the mean latency is statistically significantly 
shorter after methadone administration in HIV (-) sub-
jects but the difference in corresponding values was not 
statistically significant in HIV(+) patients. In subjects of 
both groups the mean duration is significantly increased 
after methadone administration. These results suggest 
that methadone impairs the saccadic refixation parame-
ters in HIV(+) subjects when compared to HIV(-) ones. 
HIV infection impairs motor functions, which is a con-
sequence of the negative effects of the virus on the cen-
tral nervous system. Studies support the notion that HIV 
can infect the microglial tissue and impair CNS functions 
[21,31]. The results of other research show a progressive 
decline of neuropsychological function despite effective 
Fig. 4.  Comparison of the mean duration in the AT before and after the 
administration of methadone in HIV(-) subjects
Fig. 5.  Comparison of the mean duration in the AT before and after the 
administration of methadone in HIV(+) subjects
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antiretroviral therapy and good control of viral load. This 
is associated with cerebral atrophy (including basal gan-
glia) and significant neuronal cell loss [21,27]. The virus 
can cause a variety of movement disorders due to basal 
ganglia involvement [21]. 
Eye movements are closely related to cognitive and 
emotional functions. Information on saccadic dynamics 
during certain tasks can indicate disorders of mental 
functions, which can explain the neurobiology of senso-
ry-motor systems. This may be useful in neuropsychia-
tric diagnosis. Identifying the characteristic pattern of 
psychomotor disturbances (abnormal eye movement) 
can be a valuable diagnostic tool that supports clinical 
and neuropsychological evaluation of the effectiveness 
of pharmacotherapy and psychotherapy. Currently, not 
many facts are known about the degree to which subcorti-
cal nuclei can be damaged as a result of chronic substance 
abuse (particularly opioids) and how much it influences 
functioning of the limbic loop and the reward system. 
There is a lack in the world literature of reliable, objecti-
ve research results of cognitive function and psychomo-
tor performance in patients addicted to opioids treated 
with methadone.
conclusIon
The results indicate a change in the saccade dynamics 
after methadone administration. This suggests the in-
fluence of methadone on the efficiency of the external 
eye muscles.
The observed changes in values  for eye movements may 
be due to the inhibitory effect of methadone on the CNS.
The changes in the parameters of eye movements can be 
a consequence of damage to the structures involved in 
processing visual information (frontal cortex, striatum).
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